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Bovine tuberculosis (bTB) is prevalent in intensive dairy farms in Ethiopia. Vaccination
could be an alternative control approach given the socio-economic challenges of a
test-and-slaughter control strategy. The efficacy of the BCG was evaluated on 40
Holstein-Friesian (HF) and zebu crossbred calves recruited from single intradermal
cervical comparative tuberculin (SICCT) test negative herds and randomly allocated
into two groups. Twenty-two calves were vaccinated within 2 weeks of age, and 18
were kept as a control. Six weeks post-vaccination, the two groups were exposed
and kept mixed with known SICCT test positive cows for 1 year. Immune responses
were monitored by interferon gamma (IFN-γ) release assay (IGRA), SICCT test, and
antibody assay. Vaccinated calves developed strong responses to the SICCT test
at the sixth week post-vaccination, but did not respond to ESAT-6/CFP-10 peptide
antigen-based IGRA. During the exposure, IFN-γ response to the specific peptide
cocktail [F (2.44, 92.67) = 26.96; p < 0.001] and skin reaction to the specific proteins
cocktail [F (1.7, 64.3); p < 0.001] increased progressively in both groups while their
antibody responses were low. The prevalence of bTB was 88.9% (95% CI: 65.3–98.6)
and 63.6% (95% CI: 40.7–83.8) in the control and vaccinated calves, respectively,
based on Mycobacterium bovis isolation, giving a direct protective efficacy estimate of
28.4% (95% CI: −2.7 to 50.1). The proportion of vaccinated calves with lesion was
7.0% (34/484) against 11.4% (45/396) in control calves, representing a 38% (95%
CI: 5.8–59.4) reduction of lesion prevalence. Besides, the severity of pathology was
significantly lower (Mann–Whitney U-test, p < 0.05) in vaccinated (median score = 2.0,
IQR = 0–4.75) than in control (median score = 5, IQR = 3.0–6.25) calves. Moreover,
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survival from M. bovis infection in vaccinated calves was significantly (log-rank test:
χ
2 = 6.749, p < 0.01) higher than that of the control calves. In conclusion, the efficacy
of BCG was low, but the reduced frequency and severity of lesion in vaccinated calves
could suggest its potential role in containing onward transmission.
Keywords: bovine tuberculosis, crossbred cattle, efficacy of BCG, natural transmission, Ethiopia
INTRODUCTION
In Ethiopia, bTB is an endemic cattle disease (1) characterized
by the progressive development of granulomatous lesions in the
respiratory tract and other tissues of the infected host (2). The
disease in Ethiopia is mainly caused byMycobacterium bovis, but
may be associated with other members of the Mycobacterium
tuberculosis complex in Ethiopia and other countries (3, 4).
The prevalence of bTB in Ethiopia varies with the type of
production system and breed of cattle (5–9). Intensively reared
herds, consisting of pure Holstein-Friesian (HF) cows and/or
their crosses with indigenous zebu breeds, were more commonly
affected (10–13). The number of intensive dairy farms is
increasing around urban centers in response to the prevailing
demand for dairy products (11, 12). In addition to reducing
production in infected cows (14), the disease can also be
transmitted to humans, especially as consumption of raw milk
and meat are both common in the Ethiopian society (10, 15).
The animal and public health risks dictate that controls warrant
implementation. The lack of funding to underpin a test and
slaughter control program in Ethiopia, in common with other
low- and middle-income countries (16), means that vaccination
is an attractive alternative where the disease is endemic at high
prevalence (17–19).
BCG could be a potential vaccine candidate for the control
of tuberculosis in cattle (19–21). Several evaluations have been
undertaken to determine a protective capacity of BCG in
cattle since 1911 (20–23). The results of experimental trials are
encouraging although different field trials demonstrated variable
protective efficacies [reviewed by (21)]. Several explanations were
given for the observed variability of efficacy of BCG including
variation in the strain and dose of BCG used [reviewed by (21)],
challenge model (5, 24), previous exposure to environmental
mycobacteria (25, 26), and breed and health status of study
animals (11, 27–29). In general, a recent meta-analysis reported
a relatively low direct protection of BCG against infection with
a pooled efficacy estimate of 25%, and significant reduction in
the frequency and severity of pathology of bTB in vaccinated
animals (19).
Two contact challenge efficacy trials were conducted in
Ethiopia on pure HF breed neonatal calves in which efficacies
varied between 56% (5) and 23% (12). Further studies are needed
to resolve the large difference in reported efficacy of the vaccine
and to consider its use in crossbred cattle (HF and zebu cross)
preferred in Ethiopia for the expansion of the dairy sector, as
no BCG efficacy trial has been conducted in them. This study
assessed the capacity of the BCG vaccine to protect HF–zebu
cross neonatal calves against M. bovis infection under natural
transmission settings by housing vaccinated and non-vaccinated
calves in a barn for 1 year together with cattle known to be
tuberculin reactors. We also perform a pilot study of a protein
cocktail with DIVA (Differentiating Infected from Vaccinated
Animal) properties (30) to understand its potential as a skin test




The experiment was undertaken at the National Animal Health
Diagnostic and Investigation Center (NAHDIC) at Sebeta, which
is located 25 km southwest of Addis Ababa, the capital city
of Ethiopia. Ethiopia is endemic to bTB and there is no
national control strategy for bTB in place in the country so
far. Thus, taking into account the endemicity of the diseases in
the country, the local biosecurity and safety procedures were
followed. Accordingly, an isolated barn with the holding capacity
of 120 cattle was built in the compound of NAHDIC and used for
this experiment. The barn was fenced with wire and completely
isolated from the rest of the compound. The experimental
animals were watered and fed inside this barn. The feces and
urine were removed to a septic tank through pipes connected to
the barn. The septic tank was built within the fenced area outside
the barn. The animal attendants were educated on the risk of
zoonosis and were obliged to use personal protective equipment
all the time while working in the barn. After the completion of the
experiment, all calves were slaughtered in the autopsy facilities of
NAHDIC and the carcasses were disposed by incineration.
Study Animals
A total of 60 single intradermal cervical comparative tuberculin
(SICCT) test–positive cows with an average age of 4 years were
purchased from Holeta Agricultural Research Center and used
as sources of infection (seeders). A total of 82 naïve HF × zebu
crossbred male neonatal calves were recruited at an average age
of 1 week and served for the conducting of the experiment.
The neonates were purchased from 57 SICCT test–negative dairy
farms and screened for bTB by IGRA. Thereafter, they were
randomly allocated into vaccinated and control groups. About
half of the calves were vaccinated within 2 weeks of age while
the other half were left to serve as controls. Both groups of
calves were exposed to SICCT test–positive cows at 2 months
of age and kept in contact with the cows for 1 year. The ratio
of calf to seeder was 1:1 at the start of the exposure as in
previous similar studies done in Ethiopia (5, 12). However, the
ratio was reduced to 2:1 for the last 6 months of exposure due to
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reduced space within the barn from growth of the experimental
calves. The calves were fed on pasteurized partially skimmed
milk, grass hay, and concentrate up to the age of 4 months.
Weaned calves and the reactor cows were fed on hay and
concentrate. Water was supplied to both calves and cows ad
libitum. The study was approved by the Ethical Review Board
of the Aklilu Lemma Institute of Pathobiology, Addis Ababa
University (IRB/07/2014). Unfortunately, about half of the calves
could not complete the experiment because of mortality due to
physical attack by cows, non-TB-related infections, and poor
qualities of concentrate feeds and pasteurized milk. Thus, the
analysis of the results of the study was conducted on the 22
vaccinated and 18 control calves that survived to the end of
the study.
Vaccination of Calves
The vaccine used in this experiment was a freeze-dried Russian
strain BCG vaccine produced by BB-NCIPD Ltd., Sofia, Bulgaria,
and distributed by InterVax Ltd., Toronto, Canada. Each calf in
the vaccinated group was subcutaneously administered on the
neck with 1× 106 CFU dose of BCG. The calves were vaccinated
within 2 weeks of their birth to reduce the possible influence
of environmental mycobacteria infection on the BCG efficacy
(25, 26).
SICCT Test
The SICCT test was conducted at four time points during the
experiment, at the 6th week after vaccination or before exposure
to reactor cows (month 0), and at the 4th, 8th, and 12th months
post-exposure. This test was performed using bovine and avian
purified protein derivatives (PPD-B and PPD-A) obtained from
Thermo-Fisher (Prionics, Lelystad, the Netherlands). Briefly,
0.1ml PPD-A (2,500 IU/ml) was administered intradermally on
the left side of the neck at a site tip of ear reached and the same
volume of PPD-B (3,000 IU/ml) was injected at a site 12 cm
distant from the PPD-A site in the shoulder direction. The skin
thicknesses were measured just before injection and at 72 h post-
injection by the same operator using the same digital caliper,
and the results were presented as change in skin thickness (mm)
between the two readings. The differences in the increase of
skin thickness at the bovine and avian PPD injection sites were
determined. An animal was considered to be positive when the
increase in skin thickness at the bovine PPD site was >4mm
more than the increase in skin thickness at the site of the avian
injection. If the differential increase between the two sites were
equal to or <1mm, or between 1 and 4mm, the animal was
considered negative and inconclusive, respectively (31).
DIVA Prototype Skin Test
A DIVA skin test was conducted on the experimental calves at
the same time as the SICCT test. The DIVA reagent contained
a cocktail of recombinant proteins of the ESAT-6, CFP-10, and
Rv3615c antigens ofM. tuberculosis andM. bovis (Lionex GmbH,
Germany). When preparing the DIVA reagent, equal amounts
of each freeze-dried protein were combined in a PBS solution
containing 100µg/ml of each protein (300 µg total protein/ml).
The solution was stored at −80◦C until needed. Each animal
was injected intradermally with 0.1ml DIVA solution (30 µg
total protein per dose) into the middle of the right side of
the neck. Skin thickness was measured before inoculation and
at 72 h post-inoculation. The measurements were done by the
same operator using the same digital caliper in every testing.
Results are expressed as the difference in skin fold thickness
(in millimeters) before administration of the antigens and 72 h
post-administration. Skin reaction was considered positive if
the increase in skin thickness at the injection site was ≥2mm
(20, 32).
IFN-γ Release Assay
The IGRA was performed on the sentinels every 3 weeks after
the time of vaccination and every 2 months after the start
of exposure to the reactor cows. About 5ml of blood was
withdrawn from the jugular vein of each calf into a sodium
heparinized Vacutainer tube (BD Medica, Dublin, Ireland). The
blood samples were transported to ALIPB laboratory within
8 h of sampling at ambient temperature and 250 µl of whole
blood was dispensed into flat bottom 96-well culture plates
and stimulated with mycobacterial antigens in duplicates. Each
sample was stimulated with 25 µl avian PPD (10µg/ml), 25
µl bovine PPD (10µg/ml), and 25 µl ESAT-6/CFP-10 peptide
cocktail (10µg/ml). Pokeweed mitogen (PWM; 10µg/ml) and
RPMI (25 µl per well) was used as positive and negative controls,
respectively. After incubation for 48 h at 37◦C in a humidified
atmosphere with 5% CO2, plasma supernatants were harvested
and stored at −80◦C until used for IGRA. The IFN-γ level in
the plasma supernatants were measured by the BOVIGAM kit
(Prionics, Switzerland). For comparative analysis of PPD-B vs.
PPD-A responses, a positive result was defined as a value for the
OD450 PPD-B minus the OD450 with PPD-A of ≥0.1 and a value
for the OD450 with PPD-B minus the OD450 saline stimulation of
≥0.1. Similar criteria were used to define positive result when the
OD450 value of whole blood supernatant stimulated with ESAT-
6/CFP-10 cocktail peptides minus the OD450 value of saline
stimulation (24).
IDEXX M. bovis Antibody ELISA
About 3ml of blood samples was collected in 5ml BD Vacutainer
tubes for serological examination of the experimental animals.
The samples were centrifuged at 3,500 rpm for 15min to harvest
their sera that were stored at −20◦C until processed. The sera
were tested for presence ofM. bovis–specific antibodies using the
IDEXX M. bovis antibody ELISA (IDEXX Laboratories, USA).
Serum samples and kit controls were diluted at 1:50 dilution
and tested in duplicate. The test was performed according to
the manufacturer’s instruction. Criteria for the test validity were
an OD450 ≥ 0.3 for the positive control and an OD450 ≤ 0.2
for the negative control. Results were presented as OD450 value
sample-to-positive control ratio (S/P) calculated by subtracting
the mean OD450 value of kit negative control from each sample
and dividing this value by the corrected positive-control value
(mean OD450 of positive control minus mean OD450 of negative
control). Samples with S/P ratio of ≥0.30 were considered
positive forM. bovis antibodies.
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Post-mortem and Histopathological
Examinations
Experimental calves were humanely slaughtered and their
carcasses were disposed by incineration. A detailed post-
mortem inspection was performed by a pathologist without
previous knowledge of their vaccination status. Lymph nodes
(parotid, mandibular, retropharyngeal, mediastinal, bronchial,
tracheobronchial, hepatic, and mesenteric) and seven lobes
of lung were examined in detail. The severity of lesions
was determined by applying the semi-quantitative procedure
according to Vordermeier et al. (33). Both lymph node and
lung pathology scores were summed up to a total pathology
score for each animal. Suspicious lesions were collected for
both histopathological and bacterial examinations. Tissues for
histopathological examination were fixed in 10% buffered
formalin. The fixed tissue specimens were processed using
SHANDON Citadel 1000 tissue processor, dehydrated using
graded ethyl alcohol, and then the alcohol was cleared using
xylene. Then, the tissue was impregnated in melted paraffin
using TEC2900 modular Tissue Embedding Centre (Histo-Line
Laboratories). The embedded tissue specimens were trimmed
to 4µm thickness and the tissue sections were stained with
H&E and Ziehl–Neelsen (ZN) for detection of TB granuloma
and acid-fast bacilli (AFB), respectively. Slides were examined
by light microscopy to determine the distribution of granuloma
development stages as defined by Wangoo et al. (34). Four
stages of granulomas were quantified and analyzed as previously
described (35).
Isolation of Mycobacteria
Collection of tissue specimens and isolation of mycobacteria
from those tissues were performed following the OIE manual
(31). At post-mortem, tissue specimens from lymph nodes and
lungs were collected into sterile universal bottles in 5ml of
a 0.9% saline solution and transported to the laboratory for
bacterial isolation. For calves with visible lesion, only lesioned
tissues were processed for culture, while for calves with non-
visible lesion, all head, thoracic, and abdominal lymph nodes
were processed. For bacteria cultures, the tissue samples were
homogenized with pestle and mortar, decontaminated by adding
an equal volume of 4% NaOH, centrifuged at 3,000 rpm for
15min, and neutralized with 1% (0.1N) HCI with phenol red
as an indicator. Finally, the suspensions were inoculated on two
slants of Löwenstein–Jensen media, one enriched with sodium
pyruvate and one with glycerol, and incubated at 37◦C for up
to 8 weeks. Slants were monitored on a weekly basis. Slants with
no growth at week 8 were considered negative. The colonies on
the slants were harvested, heat killed at 85◦C for 1 h in a water
bath for the release of DNA from the isolates, and then used
for mycobacterial species identification using region of difference
(RD) 4-based polymerase chain reaction (PCR) following the
procedure used by Firdessa et al. (10). Spoligotyping was
performed for identification of spoligotypes of the isolates
according to Kamerbeek et al. (36), using a non-commercial
biodyne-C-membrane produced by the Animal and Plant Health
Agency (UK).
Data Management and Statistical Analysis
Statistical analysis and graphs were made using GraphPad Prism
8. A descriptive analysis was summarized using median and
interquartile range (IQR). Tuberculosis status of the study calves
was defined by the detection of typical TB lesions in the
tissues, by culture positivity for M. bovis, or by both criteria.
Comparisons of TB gross pathology and culture positivity
between vaccinated and non-vaccinated animals were made
using Fisher’s exact-test. Direct vaccine efficacy (protection
from infection) was estimated with the formula described by
Orenstein et al. (37), which considers the incidence rates of
disease in the vaccinated and unvaccinated calves; i.e., vaccine
efficacy is the percentage reduction in the incidence rate of
disease among vaccinated calves compared with the unvaccinated
calves. Chi-square and Fisher’s exact tests were used to compare
the percentages of macroscopic and microscopic pathology in
different tissues of vaccinated and control calves. The degree
of gross pathology and bacterial load within affected tissues
between BCG-vaccinated and control calves were compared
using the Mann–Whitney U-test. The specific IFN-γ and
antibody response concentrations (optical density values at
450 nm, OD450) and skin thickness change over sampling period
in each group were compared using Friedman test (repeated
measures non-parametric analysis of variance) with Dunn’s
multiple comparison test, and repeated measures analysis of
variance with Geisser–Greenhouse correction for comparing
between the groups. The differences in immunological responses
(DIVA skin test, DIVA IGRA, and IDEXX ELISA) between
control and vaccinated groups at each testing point were analyzed
using the Bonferroni multiple comparison test. A log-rank test
(survival analysis) was used to compare the incidence rate of M.
bovis infection in the control and vaccinated groups. The non-
parametric Spearman correlation was used to assess correlation
between antibody response and pathological score as well as
between IFN-γ response to ESAT-6/CFP-10 peptide cocktail and
pathological score at the end of the experiment. A χ2-test for
trend was performed to compare the distribution of stage I–
IV lesions in vaccinated and control groups. In all cases, a 95%




Cellular and Humoral Immune Responses
Cellular Immune Response
The dynamics of IFN-γ responses in the peripheral circulation
of vaccinated and non-vaccinated calves in response to
mycobacterial antigens is presented in Figure 1. IFN-γ responses
to PPD (B-A) and ESAT-6/CFP-10 peptide cocktail–specific IFN-
γ response were low in both groups of calves before vaccination,
i.e., on day 0 (Figure 1). However, the IFN-γ response to PPD (B-
A) increased after vaccination in the vaccinated calves attaining a
peak at the third week post-vaccination with median OD450 value
of 0.29 (IQR = 0.02–0.67) and remained higher with median
Frontiers in Veterinary Science | www.frontiersin.org 4 July 2021 | Volume 8 | Article 702402
Bayissa et al. BCG Efficacy in Crossbred Cattle
FIGURE 1 | Post-vaccination IFN-γ responses in the experimental calves. The figure describes Antigen-specific IFN-γ production in whole blood cultures of 22
vaccinated and 18 control calves 6 weeks after vaccination. The released IFN-γ was measured from whole blood stimulated with PPDs (A) or specific peptides
cocktail (B) using the BOVIGAM assay. There was a statistically significant difference (p < 0.0001) in IFN-γ responses to PPD (B-A) in vaccinated and control calves at
the 3rd and the 6th week while the IFN-γ response to the peptides cocktail was not detectable in both groups of calves after vaccination. Error bars indicate the
median (±95% CI) OD450 value of the two groups for each time point.
FIGURE 2 | Post-vaccination skin test responses in the experimental calves. The figure shows skin reaction to the PPD (B-A) (A) and to the DIVA proteins cocktail (B)
in individual vaccinated and control calves after vaccination. The individual animal result is represented by a solid circle for the control group and a solid square for the
vaccinated group, and medians are indicated by horizontal lines. The change in skin thickness due to the PPD (B-A) was significantly (p < 0.01) higher in the
vaccinated calves than in the control calves while the change to the DIVA proteins cocktail was not observed in both groups of calves.
OD450 value of 0.28 (IQR = 0.17–0.47) at the sixth week post-
vaccination. At the third week vaccination, 59.1% of vaccinated
calves were positive in the differential IFN-γ responses to PPD-
B minus PPD-A while all of them were positive at the sixth
week post-vaccination. The IFN-γ responses to PPD (B-A) in
vaccinated calves significantly (p < 0.0001) increased over post-
vaccination. However, the PPD-B-specific IFN-γ response of
non-vaccinated calves stayed lower and less than that of their
PPD-A-specific IFN-γ response. Therefore, the differential IFN-γ
response to PPD-B of the vaccinated calves was significantly (p<
0.0001) greater than that of the control calves at the third and
sixth week post-vaccination (Figure 1A). However, the ESAT-
6/CFP-10 peptide-specific IFN-γ response remained at a low level
in both treatment groups during the post-vaccination period
(Figure 1B).
The median difference of skin thickness at the injection
sites of PPD-B and PPD-A was 7.7mm (IQR = 4.3–
10.6) in BCG-vaccinated calves at the sixth week post-
vaccination; the median difference in unvaccinated calves
was 0.4mm (IQR = 0.2–0.6). Among these vaccinates,
82% (n = 18) were positive in the SICCT test and this
also meant that the difference in SICCT response between
the two groups were significantly (p < 0.001) different
(Figure 2A). The DIVA protein cocktail induced <2mm skin
thickness reaction in both vaccinated and control calves
(Figure 2B).
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FIGURE 3 | Post-vaccination antibody responses in the experimental calves. Kinetics M. bovis specific antibody responses in individual control (A) and vaccinated (B)
calves are presented in the figure. The antibody response was expressed as optical density (OD) value at 450 nm and the values of each animal are connected with
lines. The antibody response in the control calves remained at low levels throughout the post-vaccination period while the response in the vaccinated calves increased
significantly at week 6 post-vaccination (Friedman test, p < 001).
FIGURE 4 | Post-exposure IFN-γ responses in the experimental calves. The figure demonstrates kinetics of IFN-γ response to PPD (B-A) (A) and ESAT-6/CFP-10
peptides cocktail (B) in the control and vaccinated calves. The IFN-γ response was measured by optical density units (OD450). Solid circle and solid square error bars
indicate the median (±95% CI) OD450 value of control and vaccinated calves, respectively.
Humoral Immune Response
Post-vaccination humoral immune responses were assessed
using the IDEXX M. bovis ELISA. On the day of BCG
vaccination, the OD450 value of the antibody response in all BCG-
vaccinated and control calves was <0.18. Antibody responses in
unvaccinated calves were undetected over the post-vaccination
period (Figure 3A). In vaccinated calves, themedianOD450 value
of specific antibody responses were 0.075 (IQR = 0.06–0.20) at
the third week and increased to 0.15 (IQR = 0.07–0.36) at the
sixth week (Figure 3B). Out of the 22 vaccinated calves, three and
an additional five calves developed detectable M. bovis protein-
specific antibody responses at the third and the sixth weeks of
vaccination, respectively. In general, the antibody responses in
vaccinated calves were significantly (p < 0.001) increased during
the 6 weeks of post-vaccination period (Figure 3).
Post-exposure Cellular and Humoral
Immune Responses
Cellular Immune Response
The median of IFN-γ response to PPD (B-A) and skin reaction
to PPD (B-A) in control calves significantly increased throughout
the exposure period. Median OD450 values of PPD (B-A)–based
IFN-γ response progressively increased from −0.04 (IQR =
−0.08 to 0.02) at the second month to 0.91 (IQR = 0.49–1.46)
at the end of the experiment (Figure 4A). Likewise, median skin
reaction to PPD (B-A) gradually rose up from 0.3mm (IQR
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FIGURE 5 | Post-exposure skin test responses in the experimental calves. The figure presents kinetics of skin reactions (in mm) to the PPD (B-A) (A) and the DIVA
proteins cocktail (B) injections in the vaccinated and control calves during 12 months of exposure. Solid circle and solid square represent the median (±95%CI) in the
control and vaccinated calves at each time point, respectively.
= −0.03 to 2.36) at the 4th month to 7.9mm (IQR = 3.7–
11.2) at the 12th month post-exposure in the control calves
(Figure 5A). The number of calves that were positive in the
SICCT test at the 4th, 8th, and 12th months were 4, 10, and
14, respectively. In contrast, the IFN-γ response to PPD (B-
A) (Figure 4A) and skin reaction to PPD (B-A) (Figure 5A) in
vaccinates declined during the first 6 months of exposure, and
then progressively increased during the second half duration of
the experiment. Median skin reaction to PPD (B-A) in vaccinated
calves were 2.6mm (IQR = 0.8–4.2), 3.0mm (IQR = 0.3–5.4),
and 4.8mm (IQR = 2.9–6.1) at the 4, 8, and 12th months
of exposure.
On the other hand, the magnitude of ESAT-6/CFP-10
peptide cocktail–specific IFN-γ responses gradually increased
in both vaccinated and control groups [F(2.44, 92.67) = 26.96;
p < 0.001] during the exposure although the intensity of
the response was stronger [F(1, 38) = 9.43; p < 0.01] in
control calves than in the vaccinated calves (Figure 4B).
However, post-hoc multiple comparison tests did not suggest
the difference between vaccinated and non-vaccinated
calves at each post-exposure testing point was statistically
significant (Bonferroni test, p > 0.05). Furthermore, intensity
of ESAT-10/CFP-10-based IFN-γ response showed a moderate
correlation (r = 0.51, 95% CI = 0.22–0.71, p < 0.001) to
pathology score.
The highest median skin reaction to DIVA proteins in
BCG-vaccinated calves was 1.3mm (IQR = 0.6–2.6) at the
end of the experiment with seven test-positive calves, followed
by 0.7mm (IQR = 0.2–1.0) at the 8th month with four
test-positive calves. In control calves, median skin thickness
change ranged from 0.5mm (IQR = 0.3–0.9) at 4th month to
3.47mm (IQR = 1.4–7.2) at 12th month exposure, with one
and 14 test-positive calves, respectively (Figure 5B). There was
a significant increase of skin reaction to the DIVA cocktail
proteins in both control and vaccinated calves [F(1.7, 64.3); p <
0.001] during the exposure period though the skin reaction
was stronger in control calves [F(1, 38); p < 0.01]. However,
similar to ESAT-6/CFP-10-based IGRA response, the difference
between vaccinated and non-vaccinated calves at each post-
exposure testing point was not found to be statistically significant
after correcting for multiple comparisons (Bonferroni test,
p > 0.05).
Humoral Immune Response
Antibody responses were undetectable in both groups of calves
after 2 months of exposure to infected animals. Median OD450
values of antibody response in unvaccinated calves ranged from
0.07 (IQR = 0.06–0.08) at the 2nd month to 0.22 (IQR = 0.10–
1.20) at the 10th month post-exposure (Figure 6). In this group,
antibody responses started to appear at the 4th month with
two test-positive calves; then the number of positive calves was
seven, six, five, and four at the 6th, 8th, 10th, and 12th month,
respectively. In contrast, positive antibody responses were not
observed in the vaccinated calves until 6 months of exposure. The
magnitude of antibody responses and number of test-positive
calves significantly (p < 0.001) increased in vaccinated group at
the 6th and 10th month compared with that of control calves.
The median OD450 value response drastically increased to 0.47
(IQR = 0.16–2.04) at the 6th month with 12 positive calves and
then decreased to 0.12 (IQR = 0.09–0.50) at month 8 with seven
positive calves, after which it rose to 0.57 (IQR= 0.20–1.94) at the
10th month with 12 positive calves (Figure 6). At the end of the
experiment, median OD450 values reduced to 0.15 (IQR = 0.08–
0.37) with only five test-positive calves. Furthermore, there was
no correlation (r =0.093, p > 0.05) between antibody response at
the end of the experiment and pathological score.
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FIGURE 6 | Post-exposure antibody responses in the experimental calves.
The figure shows dynamics of the humoral immune response in the vaccinated
and control calves during 12 months of exposure. Results were expressed by
OD450 value of the antibody response. Solid circle and solid square error bars
indicate the median (±95% CI) OD450 value of vaccinated and control calves,
respectively. The magnitude of antibody responses significantly (p < 0.001)
increased in the vaccinated calves at the 6th and the 10th month compared to
those of the control calves. Asterisks indicate months at which the skin testing
was done after exposure.
Efficacy of BCG Vaccine in Protecting
Against Bovine Tuberculosis
Pathological Examination
As presented in Table 1, visible TB lesions were found in 89%
(95% CI = 65–99) of the control calves and 68% (95% CI =
45.1–86.1) of the vaccinated calves. Thus, the direct protective
efficacy of BCG was 23% (95% CI: −7.5 to 45.3) based on visible
TB lesions. There was higher total median pathology score in
the control than in the vaccinated group, and the difference was
statistically significant (p < 0.05) (Figure 7D). The total sum
of the pathology score in the control calves was 95 (median 5,
IQR = 3.0–6.3) and 68 in the vaccinated calves (median 2.0,
IQR = 0–4.8), indicating that vaccination reduced the overall
pathology score by 38% (95% CI = 5.4–59.6) (Table 2). This
significant reduction of the pathology score was observed in the
tissues of the thoracic cavity only (Figure 7B) while there were
no significant differences in pathology scores of the head and the
abdominal lymph nodes of the vaccinated and control groups
(Figures 7A,C). Likewise, the percentage of lesioned tissue was
7.0% (34/484) in vaccinated calves and 11.4% (45/396) in control
calves with a significant (38.2%, 95% CI = 5.8–59.4, p < 0.05)
reduction in the frequency of lesioned tissue in the vaccinated
calves (Table 2). Such drop was due to the reduction (54.2%, 95%
CI= 23.0–72.8) in the thoracic cavity tissues.
Histopathological Examination
Microscopically, 89% (95% CI = 65–99) of the non-vaccinated
calves had different stages of granulomas in infected tissues while
the granulomas were seen in 59.1% (95% CI = 36.4–79.3) of
the vaccinated cattle. Thus, the vaccine protected 33.5% (95%
CI = 2.2–54.7) of the vaccinated calves from developing TB
granulomas. The frequency of occurrence of granuloma stages
in affected head and thoracic lymph nodes, and lung lobes are
presented in Figure 8. A total of 558 individual granulomas (226
from 16 vaccinates and 332 from 16 controls) were detected.
Except the 26 granulomas from mesenteric lymph nodes, the
majority of granulomas were found in the head lymph nodes,
thoracic lymph nodes, and lung lobes. Overall, 51.3% (n = 116)
of the granulomas found in affected tissues of the vaccinated
calves were at stage I, while the corresponding stage I in the
control calves was 46.1% (n = 153). Thus, the frequency of stage
I granuloma was significantly (p < 0.01) higher in the vaccinated
calves than that of the control calves. On the other hand, a
significantly higher stage IV granuloma (n = 112, p < 0.01) was
recorded in affected tissues of the control calves as compared with
its occurrence in the vaccinated calves (n = 60). On the other
hand, stages II and III granulomas were comparable in affected
tissues of both groups of calves.
Acid-fast bacilli were detected within affected tissues of seven
vaccinated calves (31.8%, 95% CI = 13.9–54.9) and 12 non-
vaccinated calves (66.7%, 95% CI = 41.0–86.7), resulting in
efficacy of 52.3% (4.5–76.1). However, the difference in the
prevalence of AFB in the affected tissue between the groups was
not significant. The median count of AFB in the granuloma of
the control calves was 3.0 while it was 1.4 in the granuloma of the
vaccinated calves; the difference between the two was significant
(Mann–Whitney U-test, p < 0.05).
Bacteriological Examination
A total of 67 isolates were obtained from culturing of lymph
node and lung tissues collected from 34 calves. Out of these,
54 isolates that were recovered from 30 calves were M. bovis
based on RD4 deletion typing and the dominant spoligotypes
were B0912 and SB0913. The remaining isolates could not give
interpretable spoligotype patterns. Group-wise, M. bovis was
isolated from 88.9% (95% CI = 65.3–98.6) of the control calves
while it was isolated from 63.6% (95% CI: 40.7–82.8) of the
vaccinated calves (Table 1). Thus, the direct protective efficacy of
BCG was 28% (95% CI=−2.8 to 50.1) based onM. bovis culture
positivity. Nonetheless, the difference in prevalence of M. bovis
culture positivity was not significant (Fisher’s exact-test, p> 0.05)
between the two groups.
Survival From M. Bovis Infection
Based on the specific peptides cocktail-based IGRA result, the
prevalence of M. bovis infection was 94.4% (95% CI = 72.7–
99.9) in the control while it was 72.7% (95% CI = 49.8–89.3) in
the vaccinated calves, resulting in direct efficacy of 23.0% (95%
CI = −1.8 to 41.8) (Table 1). The survival analysis estimated
that median duration surviving from M. bovis infection was 8
months of exposure to bTB-infected herd for non-vaccinated
calves and 11 months from BCG-vaccinated calves. There was
also a significant difference [log-rank test: χ2(1) = 6.749, p< 0.01]
in the rate of staying negative in the IGRA test between control
And vaccinated calves (Figure 9).
DISCUSSION
In the present study, the efficacy of the BCG in protecting
against bTB was evaluated in Ethiopian HF × zebu calves under
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TABLE 1 | Protective efficacy of the BCG against bTB in HF × Zebu crossbred BCG-vaccinated and control calves after 1 year of exposure to SICCT test positive cows.





calves (n = 22)
Protective efficacy
% 95% CI
Visible TB lesion 16 (88.9) 15 (68.2) 23.3 −7.5–45.3
Histopathology 16 (88.9) 13 (59.1) 33.5 2.2–54.7
Presence of AFB in infected tissue 12 (66.7) 7 (31.8) 52.3 4.5–76.1
M. bovis culture positivity 16 (88.9) 14 (63.6) 28.4 −2.7–50.1
ESAT-6/CFP-10 based IGRA* 16 (72.7) 17 (94.4) 23.0 −1.8–41.8
*IGRA after 12 months exposure.











Head lymph nodes (LNs) 7.95% (14/176) 7.64% (11/144) −4.13% 0.011 0.9166
Thoracic LNs 11.82% (13/110) 24.44% (22/90) 51.65% 5.466 0.0194*
Abdominal LNs 2.27% (1/44) 2.78% (1/36) 18.18% - >0.999
Lung lobes 3.90% (6/154) 8.73% (11/126) 55.37% 2.840 0.0920
Total pathology 7.02% (34/484) 11.36% (45/396) 38.18% 5.018 0.0251*
*p < 0.05.
FIGURE 7 | Pathology scores of the experimental calves. Comparison of pathology scores of lymph nodes of the head region (A), the thoracic lymph nodes and lungs
(B), abdominal lymph nodes (C), as well as the total pathology score (D) in the vaccinated and control calves are presented by the figure. The individual score is
represented by a solid circle for the control group and a solid square for the vaccinated group, and medians are indicated by horizontal line. The total pathology score
was significantly (p < 0.05) lower in the vaccinated calves than in the control calves that was due to the reduction of the pathology score in the tissues of the
thoracic cavity.
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FIGURE 8 | Microscopic lesion scores of the experimental calves. The Figure shows the frequency of occurrence of the different granuloma stages (I–IV) within the
head lymph nodes (A), the thoracic lymph nodes (B), and lung lobes (C) of control and vaccinated calves. The bars represent the percentage of granulomas with
different stages.
FIGURE 9 | Survival of the experimental calves from Mycobacterium bovis
infection. The figure shows reduction in the percentages of specific peptides
cocktail-based IGRA negative calves in the vaccinated and control groups
during exposure. The thick line curve represents the control calves while the
thin line curve for the control calves. There was a significant difference
(Log-rank test: χ2 = 6.749, P < 0.01) in the rate of survival from M. bovis
infection between the vaccinated and control calves.
a natural contact challenge setting. The protective efficacy of
BCG was estimated using specific peptide cocktail–based IGRA,
gross pathology, histopathology, M. bovis culture positivity, and
survival from M. bovis infection. The neonates were vaccinated
with the Russian strain of BCG at 2 weeks of age to minimize
the risk of interference of environmental mycobacterial infection
with the BCG vaccination. The absence of detectable response to
the ESAT-6/CFP-10 peptide cocktail in the IFN-γ assay and to
the DIVA skin test confirmed that all experimental calves were
free from M. bovis infection before the start of the experiment.
On top of this, post-vaccination SICCT test positivity in
the vaccinated neonates indicated the successful uptake of
the vaccine.
The evaluation of the efficacy of BCG was conducted by
housing the vaccinated and control calves for 1 year with cows
that were all SICCT test positive. After exposure to the infected
cows for 1 year, the efficacy ranging from 23.3% based on visible
lesion to 52.3% on the basis of the detection of AFB in the affected
tissues was recorded. Similarly, the observed efficacy on the basis
ofM. bovis positivity was 28.4%. Substantiating the finding of this
study, an efficacy of 28% was reported in HF calves in Ethiopia a
few years ago (12). However, the current recorded efficacy was
considerably lower than the efficacy reported by other similar
studies from Ethiopia (5), Mexico (24), New Zealand (38),
and Chile (39). The difference in the BCG efficacy recorded
by different studies can be due to variation in setting of the
experiment, strains of BCG used for vaccination, severity of
disease in the seeder animals, the sample size of experimental
calves, the pressure of transmission (ratio of calves to seeders),
age of calves at vaccination, breeds of the calves, the extent of
detailed post-mortem examination performed, the magnitude
contacts maintained between the calves and the seeders, etc. For
example, regarding the two previous Ethiopian studies, the first
study (5) was conducted on relatively few numbers of calves and
a higher efficacy was recorded. However, the sample size of the
second study (12) and that of this present study were relatively
larger and similar.
Similarly, although the seeder cows were recruited based
on results of the SICCT test, this test and other ante-mortem
bTB diagnostic tests cannot definitively indicate the disease
status of the seeders (17, 40), which makes it difficult to
estimate the pressure of infection created by seeder cows used
in different studies. Moreover, cattle-to-cattle transmission ofM.
bovis requires close contact of the susceptible animal with sources
of infection (41). Hence, the higher efficacy of 59% recorded
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in the Mexican study may be related to the use of a reactor
herd with 40% prevalence for the challenge (24), which could
have caused a less transmission pressure as compared with the
studies that have used 100% reactor herds, as it was the case in
the present study. Furthermore, the 67% efficacy estimation in
a large-scale field trial in New Zealand was likely related to the
setting of the study, in which the seeders and the naive animals
were grazing on pasture (38), in which the infection pressure
was obviously low. In addition, a recent study in Chile under a
routine farm practice reported a BCG efficacy of 66.5% (39) on
the basis of specific M. bovis antigen-based IGRA in the field
condition. Similar to the study in New Zealand, the infection
pressure was low as contact challenge was conducted in a herd
with bTB prevalence of 24%. Although the efficacy value recorded
by the present study was within the range of BCG efficacy (0 and
75%) reported from experimental studies and field trials in cattle
by different researchers from different countries [reviewed by
(19, 21)], the use of 100% positive seeders as a source of infection
could have contributed to the lower efficacy value recorded, as
compared with those studies conducted inMexico, New Zealand,
and Chile.
It is well-established that BCG vaccination does not confer
absolute protection againstM. bovis infection in cattle [reviewed
by (20, 21)]. Instead, it can considerably reduce the development
of lesions and its progression in infected tissues (5, 12). A similar
observation was made in the present trial, which evaluated the
efficacy of BCG in HF × zebu crossbred cattle for the first time.
Thus, the gross and histopathological examinations revealed a
significant reduction of the number of infected tissues and/or
severity of lesions in the vaccinated calves. Besides, the count
of AFB was significantly decreased in the affected tissues of
vaccinated calves as compared with those of the control calves.
In support of the present finding, a study conducted in Spain
reported that the proportion of AFB positivity in mesenteric
lymph nodes was significantly lower in BCG-vaccinated goats
than in the control goats (42). Such findings suggest that BCG
may play a role in limiting the multiplication of mycobacteria
within infected tissues. On top of these, BCG vaccination could
improve the incidence rate M. bovis infection in the vaccinated
calves than that of the control calves. A similar effect of BCG was
observed in a recent field study conducted in Chile (39). Hence,
BCG vaccination could play an important role in containing
the onward transmission of bTB from vaccinated cattle to
susceptible cattle.
The kinetics of the cell-mediated immune responses after
BCG vaccination and M. bovis infection was studied using the
SICCT test and the IGRA. After vaccination, IFN-γ responses
to PPD (B-A) reached a peak at the third week and remained
at higher level until the sixth week post-vaccination. However,
no detectable IFN-γ response to the specific ESAT-6/CFP-10
peptide cocktail was observed in vaccinated calves during post-
vaccination, which can demonstrate the DIVA role of the ESAT-
6/CFP-10 peptide cocktail while PPD could not achieve this role.
Earlier studies conducted in Ethiopia also reported PPD-B biased
strong IFN-γ response post-BCG vaccination (43, 44) although
non-specific IFN-γ response in calves at early age (45) and
exposure to environmental mycobacterial antigens (18) could
affect the IFN-γ response to PPD-B.
After exposure to infected cows, IFN-γ response to the specific
peptide cocktail was monitored every 2 months until the end
of experiment. During this period, a progressive increase in the
IFN-γ response was observed in both control and vaccinated
calves although the response was stronger in the control calves.
After the completion of the exposure, calves with stronger IFN-
γ response were observed to have more severe pathology as
evidenced from positive moderate correlation recorded between
IFN-γ response and pathology score. Therefore, it can be
suggested that the intensity of the specific peptide cocktail–based
IFN-γ responses may not be an indicator of protection associated
with BCG vaccination. Similarly, other studies reported that the
intensity of IFN-γ responses, after BCG vaccination, did not
correlate with protection in cattle (46, 47), suggesting that IFN-γ
response alone is not sufficient for protection. One of the possible
reasons for such absence of correlation could be associated
with duration of immunity (DoI) after BCG vaccination. In
this regard, the DoI after vaccination could be shorter and
thus, the immunity wanes while the animals are still under
exposure to infection. These studies reported variable DoI after
BCG vaccination; one of the studies suggested 6 months (30)
while the other reported 12 months (48) of DoI. In the present
study, most of the vaccinated calves generated strong IFN-
γ responses to ESAT-6-/CFP-10-specific antigens after about
6 months of exposure. In agreement with this observation,
BCG-vaccinated goats became infected in less than a year of
exposure to infected goats in Spain (49). Thus, these observations
could suggest that the DoI of BCG is <1 year requiring a
boosting dose.
On the other hand, defined proteins skin test demonstrated
its suitability as a DIVA skin test as none of vaccinated calves
were positive at the 6th week of vaccination. However, the
diagnostic sensitivity of DIVA skin test was low, especially in
vaccinated calves, compared with the SICCT test. The reason
for low sensitivity of the DIVA skin test is unclear but could
be associated with the antigenicity of the DIVA proteins used,
repeated testing, and/or immunological shift from cellular to
humoral response.
The role of the humoral immune response against bTB
and as the parameter for vaccine efficacy evaluation has been
understudied (49). However, B cells are observed in cattle
infected with M. bovis, suggesting that antibodies may play a
significant role in the control of mycobacterial infection (50).
In the present experiment, eight calves (36.4%) generated an
antibody response to BCG vaccination at the 6th week of
vaccination. Similar observations were made by previous studies
(45, 50–52). The widely used proteins for serological tests are
MPB70 and MPB83 that are expressed in low level in the BCG
strains (53, 54) as compared with their expressions in the virulent
M. bovis strains, suggesting their roles as DIVA reagents (55).
However, in the present study, eight vaccinated calves before
exposure to the infected cows tested positive in the IDEXX M.
bovis ELISA based on these proteins, which could undermine the
claim of DIVA role of these proteins.
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The first antibody reactive calves were detected at the 4th
and the 6th months post-exposure in the control and vaccinated
calves, respectively. At the end of the experiment, out of 16
control calves with visible lesion, only five were positive by the
IDEXXM. bovis ELISA. Similarly, eight calves with visible lesion
from 15 vaccinated calves were not positive with IDEXX M.
bovis ELISA. Hence, these figures suggested lower diagnostic
sensitivity of the IDEXX M. bovis ELISA for detection of M.
bovis infection. In agreement with the findings of the present
study, previous studies indicated that serological tests including
the IDEXX M. bovis ELISA have low sensitivity when they
are done before a tuberculin skin test (53, 56). In the present
study, the level of antibody response and the proportion of
animals positive for serology in vaccinates significantly increased
after 2 months of tuberculin and DIVA skin tests. Similar
to this observation, a recent study indicated a significant
increase in seropositivity in calves vaccinated with killed or
live BCG 1 month after tuberculin skin test (50). Although
previous observation indicated a positive correlation between the
antibody response to M. bovis infection and severity of the TB
disease (57, 58), such observation was not demonstrated by the
present study.
CONCLUSION
In conclusion, although the direct protective efficacy of the
BCG in protecting against bTB in HF × Zebu crossbreed calves
was low, it was demonstrated that BCG vaccination reduced
the severity and dissemination of lesions, and also delayed M.
bovis infection in the vaccinated calves. These impacts of BCG
vaccination could contribute to the containment of onward
transmission of M. bovis from vaccinated animals to other
susceptible animals.
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